RxDoctor Payments Data

Simon Patton, MD

Urogynecology and Reconstructive Pelvic Surgery · Wichita, KSNPI 1497042444

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,179 of the $1,491 with a category attached, or 79.1%. 15 manufacturers reported payments, led by Caldera Medical, Inc at 33.6% of the total. Reporting peaked in 2021 at $634 and has fallen 79.8% since, to $128 in 2025.

$1,491in general payments, 2019–2025

Across 73 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$500
  • Medtronic$268
  • Axonics, Inc.$193
  • Sumitomo Pharma America, Inc.$139
  • Boston Scientific$106
  • Pfizer$48
  • plus $236 from 9 others

What the payments were for

  • Travel & lodging$24516%
  • Food & beverage$1,17979%
  • Education$191%
  • Gifts$483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$181,819
Medicare patients
305
Services billed
4,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron338$246,835
MyrbetriqMirabegron206$128,344
Estradiol152$9,663
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst223$4,438
Clobetasol Propionate32$2,656
Solifenacin Succinate84$2,592
Trimethoprim34$1,891
Oxybutynin Chloride ErOxybutynin Chloride96$1,620
Cephalexin61$250
LoperamideLoperamide Hcl12$239
Hydroxyzine Hcl15$238
Methenamine Hippurate12$232
Ciprofloxacin Hcl45$161
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$111
Oxycodone Hcl36$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$139$246,835338 claims
Astellas Pharma US IncMyrbetriq$29$128,344206 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Kansason file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →